An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor

• Published in: The oncologist (Dayton, Ohio) Vol. 25; no. 1; pp. e60 - e67
• Main Authors: Borazanci, Erkut, Korn, Ronald, Liang, Winnie S., Guarnieri, Carol, Haag, Susan, Snyder, Courtney, Hendrickson, Kristin, Caldwell, Lana, Von Hoff, Dan, Jameson, Gayle
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.01.2020
• Subjects: Adult; Aged; DNA repair; DNA Repair - genetics; Gastrointestinal Cancer; Humans; Middle Aged; Mutation; Pancreatic cancer; PARP inhibitor; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Retrospective Studies; DNA repair; Pancreatic cancer; PARP inhibitor

Background Molecular analysis has revealed four subtypes of pancreatic ductal adenocarcinoma (PDAC). One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP‐ribose) polymerase (PARP) inhibitor olaparib. We performed a single institut...